Table 3. Univariable and multivariable Cox regression model analyses of CSS for nomogram.
| Characteristics | Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | ||
| Gender | 0.486 | ||||||
| Female | Reference | 1 | NA | ||||
| Male | 0.979 | 0.921–1.040 | 0.486 | ||||
| Age (years) | <0.001 | <0.001 | |||||
| ≤60 | Reference | 1 | Reference | 1 | |||
| 61–70 | 1.115 | 1.032–1.204 | 0.006 | 1.119 | 1.035–1.209 | 0.005 | |
| >70 | 2.008 | 1.876–2.150 | <0.001 | 1.840 | 1.712–1.979 | <0.001 | |
| Marital status | <0.001 | <0.001 | |||||
| Married | Reference | 1 | Reference | 1 | |||
| Unmarried/NOS | 1.498 | 1.412–1.590 | <0.001 | 1.247 | 1.173–1.326 | <0.001 | |
| Race | <0.001 | <0.001 | |||||
| White | Reference | 1 | Reference | 1 | |||
| Black | 1.421 | 1.291–1.564 | <0.001 | 1.322 | 1.199–1.457 | <0.001 | |
| Other/NOS | 0.926 | 0.836–1.025 | 0.137 | 0.925 | 0.835–1.024 | 0.134 | |
| Pathological grade | <0.001 | <0.001 | |||||
| I | Reference | 1 | Reference | 1 | |||
| II | 1.075 | 0.941–1.227 | 0.285 | 1.078 | 0.944–1.231 | 0.269 | |
| III | 1.696 | 1.468–1.960 | <0.001 | 1.519 | 1.313–1.758 | <0.001 | |
| IV | 1.997 | 1.520–2.624 | <0.001 | 1.594 | 1.211–2.098 | 0.001 | |
| Unknown | 1.352 | 1.153–1.586 | <0.001 | 1.042 | 0.887–1.225 | 0.615 | |
| Histological type | <0.001 | <0.001 | |||||
| Adenocarcinomas | Reference | 1 | Reference | 1 | |||
| MCC/SRCC | 1.535 | 1.396–1.689 | <0.001 | 1.410 | 1.279–1.555 | <0.001 | |
| T stage | <0.001 | <0.001 | |||||
| T1 | Reference | 1 | Reference | 1 | |||
| T2 | 0.936 | 0.741–1.181 | 0.576 | 0.925 | 0.732–1.169 | 0.514 | |
| T3 | 1.472 | 1.210–1.791 | <0.001 | 1.561 | 1.277–1.907 | <0.001 | |
| T4 | 3.344 | 2.720–4.110 | <0.001 | 2.898 | 2.343–3.586 | <0.001 | |
| N stage | <0.001 | <0.001 | |||||
| N0 | Reference | 1 | Reference | 1 | |||
| N1 | 1.147 | 1.072–1.228 | <0.001 | 1.505 | 1.401–1.616 | <0.001 | |
| N2 | 2.001 | 1.851–2.164 | <0.001 | 2.717 | 2.496–2.957 | <0.001 | |
| Surgery | <0.001 | <0.001 | |||||
| Yes | Reference | 1 | Reference | 1 | |||
| No | 3.295 | 3.044–3.567 | <0.001 | 2.221 | 1.947–2.533 | <0.001 | |
| Radiotherapy | <0.001 | 0.003 | |||||
| Neoradiotherapy | Reference | 1 | Reference | 1 | |||
| Radiotherapy* | 1.534 | 1.431–1.644 | <0.001 | 0.994 | 0.914–1.081 | 0.891 | |
| No/unknown | 1.638 | 1.519–1.765 | <0.001 | 1.178 | 1.062–1.306 | 0.002 | |
| Chemotherapy | <0.001 | <0.001 | |||||
| Yes | Reference | 1 | Reference | 1 | |||
| No/unknown | 1.553 | 1.447–1.667 | <0.001 | 1.293 | 1.172–1.427 | <0.001 | |
| RNE | <0.001 | <0.001 | |||||
| <3 | Reference | 1 | Reference | 1 | |||
| 3–5 | 0.504 | 0.444–0.572 | <0.001 | 0.800 | 0.690–0.928 | 0.003 | |
| 6–8 | 0.485 | 0.434–0.542 | <0.001 | 0.728 | 0.635–0.833 | <0.001 | |
| 9–11 | 0.463 | 0.416–0.515 | <0.001 | 0.662 | 0.579–0.756 | <0.001 | |
| ≥12 | 0.441 | 0.410–0.475 | <0.001 | 0.589 | 0.527–0.657 | <0.001 | |
| NOS | 0.710 | 0.546–0.925 | 0.011 | 0.864 | 0.660–1.131 | 0.288 | |
| Tumor size (cm) | <0.001 | .001 | |||||
| ≤5 | Reference | 1 | Reference | 1 | |||
| 5–10 | 1.341 | 1.248–1.441 | <0.001 | 1.114 | 1.035–1.200 | 0.004 | |
| >10 | 1.925 | 1.569–2.361 | <0.001 | 1.407 | 1.144–1.730 | 0.001 | |
| NOS | 1.282 | 1.187–1.385 | <0.001 | 1.088 | 1.002–1.180 | 0.043 | |
| CEA | <0.001 | <0.001 | |||||
| Negative | Reference | 1 | Reference | 1 | |||
| Positive | 1.702 | 1.577–1.836 | <0.001 | 1.450 | 1.342–1.566 | <0.001 | |
| NOS | 1.336 | 1.242–1.438 | <0.001 | 1.251 | 1.162–1.346 | <0.001 | |
*, not neoadjuvant. MCC, mucinous cell carcinoma; SRCC, signet ring cell carcinoma; RNE, Regional nodes examined; NOS, Not otherwise specified, NA, Unavailable.